Has Madaelil Thomas, MD received payments from drug or device companies?

Yes. Drug and device makers reported $782 in general payments to Madaelil Thomas, MD across 21 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Madaelil Thomas, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Madaelil Thomas, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Madaelil Thomas, MD

Cardiology · Slidell, LANPI 1417950346

Payments from drug & device makers

$782in general payments, 2019–2025

Across 21 payments — averaging $37.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boehringer Ingelheim$321
Medtronic$128
E.r. Squibb & Sons, L.L.C.$125
Lilly USA, LLC$46
Abbott$37
Novo Nordisk$32
plus $92 from 5 others

What the payments were for

Food & beverage$76097%
Education$223%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boehringer Ingelheim	5	$321
Medtronic	3	$128
E.r. Squibb & Sons, L.L.C.	1	$125
Lilly USA, LLC	3	$46
Abbott	2	$37
Novo Nordisk	2	$32
Edwards Lifesciences	1	$28
Merck	1	$22
Amgen	1	$16
AstraZeneca	1	$13
Johnson & Johnson	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

CAMZYOS$125
JARDIANCE$116

How this compares

Too few cardiology providers in Louisianato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024

$31,467

Medicare patients

143

Services billed

404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	371	$332,758
JardianceEmpagliflozin	82	$88,840
EntrestoSacubitril/Valsartan	86	$79,168
FarxigaDapagliflozin Propanediol	92	$72,866
XareltoRivaroxaban	51	$58,048
Metoprolol Succinate	388	$3,707
Rosuvastatin Calcium	245	$1,937
Atorvastatin Calcium	193	$1,500
Propafenone Hcl	26	$1,400
Amiodarone Hcl	67	$1,330
Prasugrel Hcl	15	$1,094
SotalolSotalol Hcl	49	$935
Spironolactone	190	$930
ClopidogrelClopidogrel Bisulfate	134	$887
Telmisartan	15	$588

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Boehringer IngelheimJardiance	$321	$88,84082 claims
AstraZenecaFarxiga	$13	$72,86692 claims
Johnson & JohnsonXarelto	$13	$58,04851 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cardiology providers in Louisianaon file to place this against a meaningful peer group, so we don't.